A Device Study in Healthy Participants
The main purpose of this study is to evaluate the safety and tolerability of two different devices that may be used to inject medication just under the skin. Participants will receive placebo; no active drug will be given. The study will last up to five weeks for each participant, including a one-week overnight stay in the study center.
|Condition or Disease||Intervention/Treatment||Phase|
Arms and Interventions
|Experimental: On-Body Delivery System (OBDS)/Multiple Bolus Injector|
On-Body Delivery System (OBDS)/Multiple bolus injector used to administer placebo subcutaneously (SC).
Device: On-Body Delivery System (OBDS)/Multiple Bolus Injector
Used to administer placebo SC.
|Experimental: Single Auto Injector|
Single auto injector used to administer placebo SC.
Device: Single Auto Injector
Used to administer placebo SC.
Primary Outcome Measures
- Number of Participants with One or More Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Device [Baseline through day 7]
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Overtly healthy male or female participants as determined by medical history, laboratory tests, physical examination, 12-lead ECGs, and vital signs.
Body mass index (BMI) within the range of 18 to 32 kilograms per meter squared (kg/m²)
Female participants must not be pregnant, and must test negative for pregnancy
Agree to video recording during each administration event using the autoinjector or bolus injector
Have known allergies to any components of the placebo or related compounds, or history of significant atopy, or known allergies or irritation to adhesives (e.g. skin adhesives, band aid)
Have an abnormal blood pressure as determined by the investigator
Have a history or presence of a bleeding disorder
Have a history of any types of neuropathy, radiculopathy, or fibromyalgia that would affect perception in abdominal wall
Have self-perceived dullness or loss-of-sensation on either side of the body or the abdomen
Have any condition that could affect pain perception from an injection
Have tattoos or scars over the abdomen, or other factors (eg, rash, excessive folds of skin) that, in the investigator's opinion, would interfere with injection-site assessments
Have an abnormality in the 12-lead ECG that, in the opinion of the investigator, increases the risks associated with participating in the trial
Are currently using or intend to use painkillers, aspirin, or other nonsteroidal Anti-inflammatory drugs, anticoagulant or antiaggregant drugs, over-the-counter or prescription medication for pain or inflammation
Have participated, within the last 30 days, in a clinical trial involving an investigational product. If the previous investigational product has a long half-life, 2 months or 5 half-lives (whichever is longer) should have passed
Are unwilling to stop alcohol consumption
Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
Are unwilling to abide by the tobacco restrictions
Poor peripheral venous access
Have a pacemaker and/or similar devices/other implantables
Contacts and Locations
|1||LABCORP||Leeds||United Kingdom||LS2 9LH|
Sponsors and Collaborators
- Eli Lilly and Company
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Study Documents (Full-Text)None provided.